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Profiling olfactory stem cells from living
patients identifies miRNAs relevant for
autism pathophysiology
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Abstract
Background: Autism spectrum disorders (ASD) are a group of neurodevelopmental disorders caused by the interaction
between genetic vulnerability and environmental factors. MicroRNAs (miRNAs) are key posttranscriptional regulators
involved in multiple aspects of brain development and function. Previous studies have investigated miRNAs expression in
ASD using non-neural cells like lymphoblastoid cell lines (LCL) or postmortem tissues. However, the relevance of LCLs is
questionable in the context of a neurodevelopmental disorder, and the impact of the cause of death and/or post-death
handling of tissue likely contributes to the variations observed between studies on brain samples.
Methods: miRNA profiling using TLDA high-throughput real-time qPCR was performed on miRNAs extracted from
olfactory mucosal stem cells (OMSCs) biopsied from eight patients and six controls. This tissue is considered as a closer
tissue to neural stem cells that could be sampled in living patients and was never investigated for such a purpose before.
Real-time PCR was used to validate a set of differentially expressed miRNAs, and bioinformatics analysis determined
common pathways and gene targets. Luciferase assays and real-time PCR analysis were used to evaluate the effect of
miRNAs misregulation on the expression and translation of several autism-related transcripts. Viral vector-mediated
expression was used to evaluate the impact of miRNAs deregulation on neuronal or glial cells functions.
Results: We identified a signature of four miRNAs (miR-146a, miR-221, miR-654-5p, and miR-656) commonly deregulated
in ASD. This signature is conserved in primary skin fibroblasts and may allow discriminating between ASD and intellectual
disability samples. Putative target genes of the differentially expressed miRNAs were enriched for pathways previously
associated to ASD, and altered levels of neuronal transcripts targeted by miR-146a, miR-221, and miR-656 were observed
in patients’ cells. In the mouse brain, miR-146a, and miR-221 display strong neuronal expression in regions important for
high cognitive functions, and we demonstrated that reproducing abnormal miR-146a expression in mouse primary cell
cultures leads to impaired neuronal dendritic arborization and increased astrocyte glutamate uptake capacities.
Conclusions: While independent replication experiments are needed to clarify whether these four miRNAS
could serve as early biomarkers of ASD, these findings may have important diagnostic implications. They also
provide mechanistic connection between miRNA dysregulation and ASD pathophysiology and may open up
new opportunities for therapeutic.
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Background
Autism spectrum disorders (ASD) represent a group of
childhood neurodevelopmental disorders characterized
by deficits in verbal communication and social interaction
and restricted and repetitive patterns of interests and be-
haviors. These conditions are often considered as “connec-
topathies” or “synaptopathies,” whereby neuronal circuits
are mis-wired or dysfunctional. Much progress has been
made in unravelling the genetics of ASD with large copy
number variation [1] and de novo mutations in a subset of
genes [2] as well as inherited mutations being associated
with ASD [3]. Yet, the current consensus agrees that ma-
jority of ASD cases are caused by complex interaction of
multiple genetic and environmental risk factors. Orches-
trated by environmental factors, epigenetic modifications,
such as DNA methylation, covalent modification of
histones, or the activation or silencing of genes by
microRNAs (miRNAs), may drive genetically predisposed
individuals to develop autism and represent the crossroads
between the environment and genetics in ASD. Ac-
cordingly, gene expression profiling of monozygotic twins
discordant in diagnosis of autism has identified differen-
tially expressed, neurologically relevant genes [4]. Similarly,
abnormal DNA methylation patterns have been detected
at several candidate genes in ASD patients [5].
miRNAs play key roles in neuronal development, syn-
apse formation, and fine-tuning of genes underlying syn-
aptic plasticity and memory formation [6]. Several studies
have identified aberrant miRNA expression in a wide
range of neurological diseases [7, 8], but a comprehensive
understanding of miRNA networks deregulated in ASD
has not been achieved. The expression of miRNAs in lym-
phoblastoid cell cultures of ASD patients has already been
explored [9–12], but the relevance of this cell type is ques-
tionable in the context of a neurodevelopmental disorder.
One study has identified deregulated miRNAs in the
cerebellum of ASD patients [12] and another investigated
the superior temporal sulcus and auditory cortex [13], but
it raises the issue of the investigated brain regions and the
impact of cause of death and/or post-death handling of
tissue on gene expression.
To overcome these limitations, we used olfactory
mucosal stem cells (OMSCs) biopsied from living ASD
patients and controls. OMSCs exhibit characteristics of
ecto-mesenchymal stem cell and maintain neurogenic
ability [14, 15]; they could be considered as precursor of
neuronal and glia-like cells. These characteristics make
OMSC a very relevant model for transcriptomic studies
with great potential to identify genes and pathways relevant
for neurodevelopmental disorders. Indeed, OMSC has been
used successfully to study the pathology of schizophrenia
[16], Rett syndrome [17], and Parkinson’s disease [18] in
which they displayed disease-specific alterations in gene
expression and cellular functions (for review, see [19]).
Here, using OMSC, we report a signature of miRNA
commonly deregulated in ASD. We show that this signa-
ture is conserved in primary skin fibroblast. We demon-
strate that these miRNAs have essential roles in brain
function through their regulation of neuronal specific
genes and provide evidence that deregulation of their ex-
pression alter the development of primary neurons and
the function of glial cells. Our results demonstrate the
importance of the miRNA circuitry in ASD, opening up
opportunities for the development of early diagnostic
test and potential treatment.
Methods
Ethic statements
Human samples were obtained with informed consent of
the patients, and studies were carried out under a proto-
col that was approved by the ethic committees of the
Hôpital Necker, Paris, and the Montperrin Hôpital, Aix
en Provence (CPP Marseille2). The experiments con-
formed to the principles set out in the WMA Declaration
of Helsinki and the Department of Health and Human
Services Belmont Report. All the biological collections
(blood, nucleic acid, tissues) are kept securely in one place,
and their management and the quality of their preserva-
tion follow the French regulations and ethical recommen-
dations. Primary cortical neurons were extracted from
mouse embryos (E15.5) following protocols approved by
the local ethical committee of the Interdisciplinary Institute
of Neuroscience of Bordeaux accordingly to the European
Communities Council Directive (86/809/EEC).
Patients’ information
The patients included in this study have been clinically
diagnosed as having ASD according to the criteria of
DSM-V. Full clinical description of these patients has
already been reported [20]. We include here a brief
clinical description of the patients (see Additional file 1:
Table S1). To investigate the genetic etiology, we ex-
tracted DNAs from their OMSCs and subjected to array
comparative genomic hybridization and whole exome
sequencing according to published protocol. One patient
(A3) carries two variants leading to premature translation
termination in SCN2A and FAT1, which are both recurrent
non-fully penetrant ASD genes (see Additional file 1: Tables
S2 and S3); two patients (A1 and A10) were found to carry
deletions at genomic regions 22q13.3 and 15q13.2–q13.3,
respectively, which have been found to be associated with
ASD (see Additional file 1: Table S3). The genetic etiology
of the remaining patients remained inconclusive.
Maintaining of OMSC, human primary fibroblast, and
HEK293T
OMSC was biopsied and cultivated according to published
protocol [20]. OMSC was maintained using Dulbecco’s
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modified Eagle’s medium (DMEM)/F-12 GlutaMAX™ (Life
Technologies) supplemented with Penicillin-Streptomycin
(100 U/ml) (Life Technologies) and 10 % fetal bovine serum
(FBS). Human primary fibroblasts were extracted from skin
punches with informed consents and maintained in RPMI
1640 Medium GlutaMAX™ (Life Technologies) supple-
mented with Penicillin-Streptomycin (100 U/ml) (Life
Technologies) and 10 % FBS. HEK293T cells were main-
tained in DMEM High-Glucose Medium GlutaMAX™ (Life
Technologies) supplemented with Penicillin-Streptomycin
(100 U/ml) (Life Technologies) and 10 % FBS. Both cell
types were passaged first by detaching using 0.05 %
Trypsin-EDTA (1×) Phenol Red (Life Technologies)
and replated in desired concentration.
Expression profiling of miRNA
miRNAs were extracted from frozen pellets using mirVa-
naTM miRNA isolation kit (Life Technologies) according
to manufacturer’s instructions. Concentration was mea-
sured using Nanodrop 2000 (Thermo Scientific). During
the discovery phase, miRNA profiling was performed
across a two-card set of TaqMan® MicroRNA Arrays (ar-
rays A and B) (Life Technologies) for a total of 667 unique
assays specific to human miRNAs (Sanger miRBase v10).
Analyses were done in technical triplicates and used two
different miRNA extractions from two pellets. For valid-
ation, 24 miRNAs that were found either significantly
deregulated in the first round or whose assays failed and
the 7 reference miRNAs were assessed (see Additional
file 1: Figure S1). Raw data (see Additional file 2) were
analyzed using both GenEX and RealTime StatMiner®
software. Both integrate quality controls, selection of best
endogenous controls, clustering, differential expression,
and two-way ANOVA analysis. The samples included in
miRNA profiling were A2, A3, A5, A6, A7, A9, A10, and
A11 vs. C1, C4, C5, C6, C7, and C10. The miRNA profiling
and analyses were performed as paid service by the IMA-
GIF platform for high-throughput quantitative PCR, ICSN
CNRS, Gif-sur-Yvette, France. Expression profiles of miR-
146a, miR-221, miR-654-5p, and miR-656 were assessed
using Taqman assays on Fluidigm 48.48 array in technical
triplicates; for fibroblast samples, two different miRNA ex-
tractions from consecutive passages were analyzed and six
miRNAs were used as reference miRNAs (see Additional
file 1: Figure S2 and Additional file 2 for raw data); for
peripheral blood mononuclear cells (PBMC), only one
extraction was analyzed and seven miRNAs were used as
reference miRNAs (see Additional file 1: Figure S3 and
Additional file 2 for raw data). Sample preparation was
done according to the manufacturer’s Protocol for Creating
Custom RT and Preamplification Pools using Taqman®
MicroRNA Assays (Life Technologies). This step was
performed as paid service by Platform qPCR-HD-GPC,
Ecole Normale Supérieure, Paris, France.
miRNA target prediction and pathway analysis
Target prediction was performed using mir-DIP which
integrates predictions from multiple software. Only tar-
gets predicted by at least three different programs were
included in pathway analysis. Gene ontology enrichment
of predicted miRNA targets (~1000 targets per miRNA)
was performed using ingenuity pathway analysis (IPA).
Quantitative real-time polymerase chain reaction
Total RNA was extracted using TRIzol reagent (Life
Technologies) and RNeasy Mini Kit (QIAGEN) with
DNase I treatment step (QIAGEN). cDNA was reversed
transcribed from extracted RNA using SuperScript® II
Reverse Transcriptase (Life Technologies). Gene expres-
sion was measured using SYBR Green Power Mix (Life
Technologies) using primers specific for each gene.
Additional file 1: Table S4 contains the sequences of all
primers used in this study. Relative standard curve method
was employed to calculate relative gene expression. Reac-
tions were performed using the Step One Plus Real-Time
PCR system (Applied Biosystems). Expression values were
taken from mean of triplicates.
Cloning the 3′UTR of GRIA3, KCNK2, and MAP2
The entire or parts of the 3′ untranslated region
(UTR) of GRIA3 (~2000 bp), KCNK2 (~1300 bp), and
MAP2 (~1300 bp) were amplified using specific primers
(Additional file 1: Table S4), subcloned into TOPO 3.1
vector using TOPO® TA Cloning® Kit (Life Technologies)
and transformed into One Shot® TOP10 Chemically Com-
petent E. coli (Life Technologies) by heat shock method.
Plasmid was extracted using PureYieldTM Plasmid Mini-
Prep System (Promega) and digested with XhoI and NotI-
HF (New England Biolabs). Digested fragment was gel
purified once more then cloned into cut psiCheck2
plasmid (Promega) using T4 DNA Ligase (New England
Biolabs). For higher yield plasmid extraction, 100 ml of bac-
terial culture was subjected to Plasmid Midi Kit (QIAGEN).
Cloned plasmids were sequenced using psiCheck2_hLucF
and psiCheck2_hLucR for screening.
Dual luciferase assay
Approximately 2 × 105 HEK293T cells were plated in
each well of 12-well plate the day before transfection.
Cells were transfected with either plasmids overexpress-
ing miRNAs, LentimiRa-GFP-mmu-mir-146a/221/656
(mm10082/mh10296/mh10968, ABM Good) or empty
vector LentimiRa-GFP-empty (m001, ABM Good), together
with psiCheck2_GRIA3_UTR, psiCheck2_KCNK2_UTR,
or psiCheck2_MAP2_UTR plasmids (ratio 1:3 to ensure
good expression of luciferase). Transfection was per-
formed using JetPRIME® Polyplus Transfection Reagent
(Ozyme) following manufacturer’s instruction. Assay
was performed using Dual-Luciferase® Reporter Assay
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System (Promega) 24 h after transfection. Ratio of
Renilla luciferase to firefly luciferase was taken as mean
of technical triplicates.
In situ hybridization analysis
Tissue preparation and processing
Male, 2-month-old wild type mice were deeply anesthe-
tized using pentobarbital and fixed by intracardiac perfu-
sion with 4 % paraformaldehyde in phosphate-buffered
saline (PBS). Brains were removed, post-fixed overnight at
4 °C, and cryo-protected using two baths of Tris-HCl buff-
ered saline (TBS) with 0.5 M sucrose at 4 °C during 48 h.
Brains were then frozen in bath of isopentane at −35–40 °C
and stored at −80 °C. Serial sections of 20 μm were done in
a cryomold (Tissue-Tek) with a cryostat (Leica), mounted
on Superfrost Plus glass slides (Thermo Scientific), and
preserved at −80 °C. For embryos and early postnatal ani-
mals, intracardiac perfusion was replaced by direct 4 %
paraformaldehyde fixation overnight after decapitation.
In situ hybridization procedure
Tissue sections mounted on glass slides were thawed
and air dried for 1 h at room temperature, incubated in
a solution containing 20 μg/ml proteinase K (Sigma) in
TBS, pH 7.4 for 3 min, and then washed for 5 min two
times in TBS. Samples were fixed in 4 % paraformalde-
hyde (PFA) for 10 min and washed with 2 mg/ml glycine
in TBS and twice for 5 min in TBS. To remove residual
phosphate from the TBS washes, slides processed with
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)
fixation were incubated twice for 10 min in freshly prepared
solution containing 0.13 M 1-methylimidazole, 300 mM
NaCl, pH 8.0 adjusted with HCL. In the meantime, a solu-
tion of 0.16 M EDC (Sigma) is prepared by adding EDC
into 1-methylimidazole and 300 mM NaCl (pH 8.0) solu-
tion. The pH of the EDC solution is readjusted by adding
12 M HCl to pH 8.0. Slides are maintained in a humidified
chamber for 1 h at room temperature incubated in 500 μl
of EDC solution to each slide. The slides are then washed
in 2 mg/ml glycine/TBS solution and then twice for 5 min
in TBS. For enzymatic inactivation, slides were acetylated
by incubating for 30 min in a solution of freshly prepared
0.1 M triethanolamine and 0.5 % (v/v) acetic anhydride.
Slides were then rinsed twice for 5 min in TBS. For
pre-hybridization, the tissue sections were covered
with 500 μl of hybridization buffer containing 50 %
formamide, 5× SSC, 5× Denhardt’s solution, 0.25 mg/ml
yeast transfer ribonucleic acid (tRNA), 0.5 mg/ml salmon
sperm DNA, 20 mg/ml blocking reagent (Roche),
1 mg/ml 3-((3-cholaminodopropyl) dimethylammonio)-1-
propanesulfate (CHAPs, Sigma), and 0.5 % tween at room
temperature for 2 h in a humidified chamber. The
hybridization buffer was removed by tilting the slide.
Sequences of the different probes are described in
Additional file 1: Table S4. For hybridization, 40 nM of
DIG-labeled locked nucleic acids (LNA) probe (mmu-
miR-146a, mmu-miR-scramble) diluted in hybridization
buffer were applied per section and covered with cover-
slips. The slides were incubated in a sealed humidified
chamber for 16 h at 42 °C.
Slides were immersed for 3 min in 2× SSC at 52 °C
and then washed for 5 min twice in 1× SSC at 52 °C and
once in 1× SSC at room temperature. Slides were
washed again for 5 min twice in 0.2× SSC at room
temperature and once in TBS. In preparation for probe
detection, 500 μl of blocking solution containing 5 mg/ml
blocking reagent (Roche), 10 % (v/v) normal goat serum,
and 0.1 % (v/v) tween in TBS was applied to each slide for
1 h at room temperature in a humidified chamber. Anti-
body anti-DIG-FAB peroxidase (POD) (Roche) diluted
1:500 in blocking solution was incubated overnight. Slides
were then washed three times in TBS. Slides were incu-
bated in freshly prepared NBT/BCIP substrate reagent
containing 50 mM MgCl2, 100 mM NaCl, 0.2 mM Lev-
amisole, 0.5 mg/ml NBT, and 0.1875 mg/ml BCIP in
100 mM TBS pH 9.5 and protected from light during the
exposure time (approximately 6 h). Slides were then
washed twice in water, then twice in TBS and incubated
for 10 min in 4 % PFA solution. Finally, slides were
washed in water and mounted using two drops of
mounting medium.
Immunohistochemistry and miRNA ISH co-staining
To assess cellular localization of miR-146a, brain sec-
tions were processed for both immunofluorescence
staining and in situ hybridization (ISH) staining.
Slides were washed three times in PBS and then in-
cubated 1 h at room temperature in humidified
chamber, with 500 μl of blocking solution containing
0.1 % (v/v) triton-100× and 2 % (v/v) normal donkey
serum in PBS. The blocking solution was removed by
tilting the slide. Slides were incubated overnight at
room temperature with the same blocking solution
containing polyclonal antibody against Fox3/NeuN
(1:1000; Abcam, AB104225) for specific neuronal stain-
ing and antibody against GFAP (1:500; Abcam, ab7260).
Slides were rinsed three times in PBS and incubated for
1 h 30 min at room temperature with donkey Alexa fluor
488-conjugated anti-rabbit (for NeuN), secondary anti-
body diluted in blocking solution. After being rinsed
in PBS, then water, slides were mounted in mounting
medium.
Microscopy and image processing
Images were captured on an upright epifluorescence
microscope, Nikon Eclipse Ni-U (Nikon France S.A)
using 10× objective CFI Plan Fluor NA 0.30 and 40×
objective CFI Plan Fluor NA 0.75. For fluorescent imaging
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filters, sets for GFP were used, and pictures were acquired
using a Zyla SCMOS camera (Andor Technology Ltd.,
Belfast, UK).
Primary neuronal cultures
Cultured mouse hippocampal neurons were prepared from
E16.5 embryos, grown on 18-mm glass coverslips coated
with laminin/polylysine and maintained in Neurobasal B27-
supplemented medium. Neurons were transfected using
Lipofectamine 2000 on days in vitro 11 (DIV11) with
800 ng of plenti-III-miR-GFP-Blank or pLenti-III-miR146a-
GFP, and experiments were performed at DIV18.
Sholl analysis
Analysis of the dendritic morphology was done blind to
the genotype. Sholl analysis was done using a Sholl ana-
lysis pluggin on ImageJ and determined the number of
dendritic branch intersections with concentric circles of
increasing radii (interval of 10 μm) from the soma. All
neurons were imaged at the same magnification, and im-
ages were threshold, and to avoid false intersections be-
cause of noise, each threshold images were checked and
compare to the original. The BI (branching index) was
shown: The BI compares the difference in the number of
intersections made in pairs of circles relative to the dis-
tance from the neuronal soma, following the following
equation: BI = ∑(intersections circle n − Intersections cir-
cle n − 1).rn according to “A new mathematical function
to evaluate neuronal morphology using the Sholl ana-
lysis: Luis Miguel Garcia-Segura, Julio Perez-Marquez”.
Virus production
Lentivirus was produced using lentiviral compatibility
vectors as mentioned above by the Plateforme Vecterus
Viraux et Transfert de Gènes from Hospital Necker as
paid service. Viral titre was determined by FACS of GFP
signal. For all experiments, virus infection was per-
formed at the multiplicity of infection (MOI) of 2 in nor-
mal media; virus media was replaced after at least 4 h of
incubation.
Primary astrocyte culture
Astrocytes were extracted from cortexes of P1 mice
and grown on uncoated flask in DMEM Low Glucose
Medium GlutaMAX™ (Life Technologies) supplemented
with Penicillin-Streptomycin (100 U/ml) (Life Technolo-
gies) and 10 % FBS. When cell reach 70–80 % confluent,
they were detached with 0.05 % Trypsin-EDTA (1×) Phenol
Red (Life Technologies) and replated in desired cell density;
this passaging step was only performed once for each cul-
ture. For cell growth assay, 20,000 cells were replated into
E-Plate 96 for continuous monitoring on the Xcelligence
RTCA-MP instrument (ACEA Biosciences) for 5 h before
being infected with virus; growth rate was measured over
72 h during which cell index was analyzed every 15 min.
Growth rate was measured as slope of normalized cell
index from at least three technical triplicates over a set
period of time; this analysis was performed using RTCA
Software V2.0 (ACEA Biosciences).
For glutamate uptake assay, 200,000 cells were replated
into a 24-well plate and allowed to reach 100 % confluent.
Cells were then treated with a mitotic blocker 8 μM cyto-
sine β-D-arabinofuranoside (Sigma) for 5–6 days followed
by a 90-min incubation with 75 mM L-leucine methyl
ester (Sigma) to completely diminish the culture of micro-
glia; viral infection was performed overnight. The next
day, cells were serum starved for 2 h before being incu-
bated in media containing 1 μCi/ml (H3)-glutamic acid
(Perkin Elmer) and 50 μM of unlabeled glutamate (Sigma);
uptake was allowed in the incubator for 30 min before
cells were washed three times with ice cold Hanks’ bal-
anced salt solution (Life Technologies) supplemented with
HEPES 15 mM (Life Technologies) and lysed in 1 M
NaOH 0.1 % Triton-X solution at 42 °C for 10 min. For
negative control, the transporters were blocked using
250 μM L-trans-pyrrolidine-2,4-dicarboxylic acid (PDC)
(Sigma) (maintained even during the serum starved step).
Radioactivity was measured as average count per minute
during 10 min. Rate of uptake was measured from dupli-
cates, normalized to samples treated with PDC, and the
protein concentration was measured by Bradford assay.
Results
Identification of miRNA deregulation signature in ASD
We harvested OMSCs from the lamina-propria layer of
the nasal cavities of living ASD patients and age and sex
matched controls (see Additional file 1: Table S1) and
profiled 667 miRNAs (Sanger miRBase v10) in eight pa-
tients and six controls using the TLDA high-throughput
real-time qPCR approach. The genetic etiology of these
patients is mostly unknown according to whole exome
sequencing and array comparative genomic hybridization
analyses (see Additional file 1: Tables S2, S3). In keeping
with the current gold standard in miRNA analysis, miRNA
relative quantity were calculated using ΔCt method using
the geometrix mean of seven house-keeping miRNAs miR-
let-7g, miR-106a, miR-151-3p, miR-15b, miR-16, miR-17,
and miR-99b (see Additional file 1: Figure S1) and the aver-
age of all controls for normalization [21, 22]. Twenty four
miRNAs which were either found significantly deregulated
in the patient groups (corrected P values <0.05) or for
which the PCR assay failed originally were included
in the second round for validation (see Additional file 1:
Figure S1). These analyses identified four miRNAs, miR-
146a (upregulated twofold), miR-221, miR-654-5p, and
miR-656 (all three down-regulated ~1.3-fold), significantly
deregulated in the patients (P < 0.05) (see Fig. 1a). miR-
654-5p and miR-656 are conserved only in the primate
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chain and are expressed at low level in the human brain;
by contrast, miR-146a and miR-221 sequences are 100 %
conserved in the mouse and are highly expressed in differ-
ent human brain regions throughout development includ-
ing the cortex, hippocampus, and cerebellum (Allen Brain
Atlas, Brain Span) [23], supporting a role in development.
Tissue and disease specificity of the miRNA signature
We next questioned the tissue specificity of this miRNA
signature and tested miRNA expression in different cell
types. For this, we collected either primary skin fibro-
blasts from 5 new ASD patients and 4 controls or per-
ipheral blood mononuclear cells (PBMC) from 9 ASD
patients (3 of whose fibroblasts were also analyzed) and
20 controls (see Additional file 1: Table S5). Indeed, pri-
mary human fibroblasts are readily accessible untrans-
formed cells that have been previously used as model for
neuropsychiatric disorder studies [24, 25], and PBMCs
are suitable for screening of large cohorts. Since no prior
standard for reference miRNAs in fibroblast or PBMC
exist, we analyzed the same 7 reference miRNAs (miR-
let-7g, miR-106a, miR-151-3p, miR-15b, miR-16, miR-17,
and miR-99b) as the above analysis and U6, a non-
coding RNA normally used as reference for miRNA
assay. We excluded miRNAs with the most variations
between groups, miR-99 and U6 (in fibroblasts) and
miR-16 (in PBMC), from being used as reference miR-
NAs (see Additional file 1: Figure S2, S3). This analysis
showed a significant deregulation of miR-146a, miR-221,
and miR-654-5p in the ASD group compared to controls
in the same trend as in OMSC (see Fig. 1b). By contrast,
no differential expression of the four miRNAs could be
detected in PBMC from ASD patients compared to
controls (see Fig. 1c). We then raised the issue of the dis-
ease specificity of this signature in related neurodevelop-
mental disorders and extended the analysis to primary
a 
** 
* 
* 
** Re
la
tiv
e 
ex
pr
es
si
on
 
0 
4 
2 
6 Controls (n=6) 
ASD (n=8) 
miR-146a 
0 
20 
40 
60 
R
el
at
iv
e 
ex
pr
es
si
on
 
*** 
* 
b
R
el
at
iv
e 
ex
pr
es
si
on 2 
1 
Controls (n=20)
ASD (n=9)
c 
miR-221 miR-654-5p miR-656 
1 
0 
4 
2 
3 
Controls (n=4) 
ASD (n=5) 
ID (n=12) 
*** 
*** 
*** *** 
R
el
at
iv
e 
ex
pr
es
si
on
 5 
6 
Fig. 1 Identification of a conserved miRNA signature in ASD. a Significantly deregulated miRNAs after validation in ASD OMSC after the validation
round, representing the miRNA deregulation signature of ASD: miR-146a, miR-221, miR-654-5p, and miR-656 (±SD, controls—dark gray bar, patients—light
gray bar). Dots represent average of technical triplicates for each biological repeat. *P< 0.05, **P< 0.01 by Wilcoxon rank sum test. b Tissue and disease
specificity of miRNA signature. Expression (±SD) of miR-146a, miR-221, miR-654-5p, and miR-656 were assessed in primary skin fibroblasts of ASD patients
(n= 5, light gray bar), ID patients (n= 12, white bar), and controls (n= 4, dark gray bar). Results were obtained from Taqman assays performed on Fluidigm
array. Dots represent average of technical triplicates for each biological repeat. *P< 0.05, ***P< 0,001 by Student’s paired two-tailed t test. c Expression
(±SD) of miRNA signature in peripheral blood mononuclear cells (PBMC). No significant difference in miR expression was detected between the controls
(n = 20, dark gray box) and the ASD patients (n = 9, light gray box). Results were obtained from Taqman assays performed on Fluidigm
array. Dots represent average of technical triplicates for each biological repeat
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skin fibroblasts from patients who have known causes of
intellectual disability (ID) without autistic features (n = 12)
(see Additional file 1: Table S6). Our results showed that
ID patients do not share the same signature as ASD (see
Fig. 1b). Yet, miR-146a was also found significantly upreg-
ulated in the ID group, supporting the role of this miR-
NAs in shared pathways affected in both conditions.
Moreover, the level of miR-221, miR-656, and miR- 654-5p
transcripts observed in the ID group suggests that
these miRNAs could be used to develop a diagnostic
panel allowing the distinction between the ASD, ID,
and the control groups.
miRNA expression deregulation is not mediated by DNA
variations
To get insight into the mechanism underlying deregu-
lated miRNA expression, we search for DNA variation in
the miRNA regions that could account for the differen-
tial expression observed between ASD and controls. We
first re-analyzed the results of the array comparative
genomic hybridization and whole exome sequencing
analyses previously performed for all patients. Neither
copy number nor single nucleotide polymorphism (SNP)
was identified in the exonic region nor in the immediate
captured region flanking the miRNAs. The presence for
variant within the promoter region could not be investi-
gated as the corresponding sequences have not been
precisely defined. Yet, we performed capillary sequen-
cing to assess the distribution of a known expression
quantitative trait locus SNP (rs57095329) in the pro-
moter of miR-146a in both cohorts (control and patient)
[26]; only one patient fibroblast sample carries this SNP,
ruling out its contribution to the expression difference
detected. Collectively, these data suggest that the abnor-
mal miRNA expression observed in ASD patients’ cells
is likely due to transcriptional deregulation or altered
posttranscriptional processing of pri-miR transcripts.
ASD-deregulated miRNAs target neuronal relevant genes
and pathways
Next, we searched for putative messenger RNA (mRNA)
targets deregulated in patients’ OMSCs. Using miR-DIP
to integrate target prediction from multiple programs,
we found that on average, 1000 targets predicted for
each miRNA by at least three different prediction pro-
grams. We integrated the prediction analyses with that
of pathway enrichment using ingenuity pathway analysis
and identified several highly relevant pathways (see Fig. 2a
and Additional file 1: Table S7). These are neuronal path-
ways, including axonal guidance signalling, signalling by
Rho Family GTPases, actin cytoskeleton signalling, and
synaptic long-term potentiation (see Additional file 1:
Figure S4), as well as immunological pathways which
include IL-8 signalling, CXCR4 signalling, and macro-
pinocytosis signalling (see Fig. 2a).
To validate some of these in silico predictions, we
assayed by RT-qPCR the transcript levels for several
known and predicted miRNA targets involved in the
identified pathways (see Fig. 2b). Albeit not significant,
decreased levels of GRIA3 and KCNK2 transcripts and
increased levels of MAP2 mRNA were found in patients’
OMSCs (see Fig. 2b). Using a dual luciferase reporter
assay, we confirmed that these transcripts are direct
targets of the identified miRNAs. Overexpressing either
miR-146a, miR-221, or miR-656 significantly reduced the
luciferase activity of reporter constructs carrying the
3′-untranslated region (3′-UTR) of GRIA3, KCNK2.
and MAP2 (see Fig. 2c).
miR-146a and miR-221 displays strong expression in
regions important for high cognitive functions
In the mouse brain, the expression pattern of miR-146a
and miR-221 strongly correlates with that in the human
brain (Allen Brain Atlas, Brain Span); they are expressed
throughout the cortex, hippocampus, and amygdala as
evidenced by in situ hybridization (see Fig. 3a). During
development, both miRNAs exhibit an initially high and
widespread expression that becomes restricted to some
cellular layers in the above-cited postnatal brain regions
(see Fig. 3b). In situ hybridization associated with the
immune-detection of cell-specific markers showed that
in the adult mouse brain, miR-146a and miR-221 are es-
sentially expressed in neurons (see Fig. 3c), whereas very
few signal was detected in the glial lineage (see Fig. 3c).
miR-146a overexpression affects astrocyte glutamate
uptake capacity and neuronal dendritic arborization
The current consensus is that ASD physiopathology is
based on either defective neural connectivity, excitatory-
inhibitory neural activity imbalance, disturbed dendritic
morphology, or neuroimmune disturbances. Therefore,
we tested whether miR-146a overexpression could affect
any of these processes using primary neuronal and glial
cell cultures transduced with lentiviral constructs driving
miR-146a expression. Primary astrocytes were cultured
from cortexes of P1 mice and infected with lentiviral
virus at multiplicity of infection of 2 (efficacy 100 %) to
induce roughly 6.5-fold upregulation of miR-146a (see
Fig. 4a). Significant reduction of known targets, Nlgn1
[27] and Traf6 [28], was confirmed by RT-qPCR (see
Fig. 4a). Compared to astrocytes infected with the empty
lentiviral vector (control), astrocytes overexpressing miR-
146a displayed a significant decrease in growth rate as
assessed by Xcelligence growth assay (see Fig. 4b), consist-
ent with previous published evidence [29]. Most interest-
ingly, these astrocytes also exhibited a significant increase
in glutamate uptake capacities (see Fig. 4c), suggesting a
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defect in either the regulation of the transport and/or pro-
cessing and/or the metabolism of the glutamate. Quantifi-
cation of the transcript and protein levels of the two glial
specific glutamate transporters (SLC1A2 and SLC1A3),
the glutamate dehydrogenase (GLUD1), and the glutamine
synthetase (GLUL) failed to identify any marked alteration
(data not shown). The precise mechanism of how miR-
146a controls this core function of astrocyte remains to
be investigated.
To further explore the consequence of miR-146a up-
regulation on neuronal cells morphology, we assessed
dendritic arborization extent and complexity of primary
neuronal cultures transduced with the same lentiviral
constructs using Sholl analysis. When compared to
GFP expressing cells transfected with a blank construct,
miR-146a overexpressing neurons displayed shriveled
dendritic trees with branching points occurring more
proximal than in control conditions (see Fig. 4d). This
suggests that the level miR-146a expression in also an
important determinant for neuronal development.
Discussion
We report here a comprehensive analysis of miRNA
expression profiles in human stem cells from ASD pa-
tients. We identified a signature of four miRNAs (miR-
146a, miR-221, miR-654-5p, and miR-656) commonly
deregulated in ASD. This signature is not conserved in
PBMCs, a result consistent with the two previously
b
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reported miRNA expression studies performed in serum
from children with autism [30, 31], but is also observed
in primary skin fibroblasts from unrelated patients. While
this observation may restrict the ease to rapidly validate
our data in a larger cohort, it highlights the relevance of
OMSCs, a neurologically relevant tissue, for understanding
the pathophysiological mechanisms underlying neurodeve-
lopmental disorders and supports the use of primary fibro-
blasts for routine testing. Notably, comparable miRNA
profiling in OMSCs was recently performed in the context
of schizophrenia [32], and similar results were obtained
with increased miR-382 expression observed in OMSCs
samples from patients but not in peripheral blood-derived/
non-neuronal samples. Despite the limited number of sam-
ples tested, potentially restricting the statistical power, the
observed conservation of the signature in primary skin
fibroblasts from unrelated patients strongly supports its
biological relevance. Lastly, our finding that ID patients do
not share the same signature as ASD may have diagnostic
implications and raises the possibility of using miRNA
signature as a biomarker for ASD, providing a means
for detecting early signs of the disease and allowing
early intervention.
Target prediction analysis suggests that the transcripts
regulated by these miRNAs code for proteins involved
in neurodevelopmental processes as well as immune
response and inflammation, both of which are relevant for
the pathology of ASD. Previous studies have demonstrated
that immune imbalance impairs higher order brain func-
tioning and altered inflammatory responses have been
reported in ASD patients [33, 34]. Moreover, DNA methy-
lation analysis of the autistic brains has identified a very
significant enrichment of differentially methylated region
in genomic areas responsible for immune functions [5].
Along these lines, it is noteworthy that miR-146a was first
identified as an immune system regulator and possibly
plays an important role in neuroinflammation [28]. Our
results support the hypothesis that altered miR146a ex-
pression contributes to the neuroinflammatory processes
reported in the autistic brain.
miR-146a and miR-221 have also established roles in
neurodevelopment. Validated targets of miR-146a in-
clude MAP1B, which regulates AMPA receptor endo-
cytosis [35], while direct targets of miR-221 include
FMR1, the fragile X gene which is the most frequent
cause of syndromic intellectual disability (ID) and ASD
[36]. Using target prediction tools combined to dual lu-
ciferase assays and Western Blot analysis, we identified
additional neuronal transcripts regulated by these miR-
NAs. We showed that GRIA3 is a target transcript for
both miR-146a and miR-221. GRIA3 encodes a core sub-
unit of the AMPA receptor, and findings from various
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Hippocampus
Amygdala
Entorhinal
cortex 
miR-146a miR-221 
a b
c 
E11 
E16 
P5 
P30 
Fig. 3 Expression of miR-146a and miR-221 in the brain. a ISH of miR-146a and miR-221 in the adult mouse brain. Typical coronal slices showed
elevated miR-146a in the hippocampal CA1 and dentate gyrus (DG), the amygdala nuclei (amyg), and the entorhinal cortex (ctx). b Hybridization
of scramble or miR-146a and miR-221 was performed onto mice at different developmental from embryonic (E11 and E16) and postnatal (P5 and
P30) stages. Arrows indicate hippocampal formation or territories at the different age, allowing appreciation of the specific labeling of different
cellular layers in the postnatal brains. c Neuronal expression of both miRNAs was confirmed by combining miR-ISH with fluorescent labeling of
neuronal (NeuN) and glial (GFAP) cells in the CA1 region
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experimental systems implicate ionotropic GluR dysfunc-
tion in ASD [37]. miR-146a upregulation in ASD neurons
might thus alter AMPA receptor biology through both
impaired MAP1B-mediated endocytosis and decreased
amount of GRIA3. We also demonstrated that miRNA
expression deregulation correlates with a reduced level of
KCNK2 protein in patients’ OMSCs and that both miR-
146a and miR-221 directly target KCNK2 3′UTR. KCNK2
is a member of the potassium leak channel family, a group
of proteins that are critical determinants of neuronal
excitability in the cortex [38], and KCNK2 knockdown
impairs neuronal migration in the developing mouse
cerebral cortex [39]. Reduced amount of KCNK2 protein
may thus contribute to the failure or delay in neur-
onal migration that has been observed in some cases
of autism and ID.
One prevalent theory for the pathogenesis of autism
relates to a deficiency in the plasticity of axonal sprouting
and synaptic connectivity. There have been reports in aut-
ism cases of enlarged or abnormally oriented neurons,
densely packed neuronal regions, and isolated regions of
atrophic neurons with reduced dendritic arborisation
[40, 41]. Increased spine density has also been reported in
fragile X syndrome [42]. Conversely, neuronal atrophy and
reduced dendritic spines is mentioned in Rett syndrome
[43]. Our observation that miR-146a overexpression dis-
turbs neuronal dendritic arborization is thus consistent
with the defective neural connectivity found in ASD.
miR-146a has also been linked to the processes under-
lying glial cells differentiation, and previous reports
demonstrated that it inhibits the expression of neuron-
specific targets Nlgn1 and Syt1, preventing glial cells
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from mistakenly adopting neuron-specific phenotypes
[27]. Using in vitro assays, we demonstrated that miR-
146a overexpression alters astrocyte glutamate uptake
capacity. Interestingly, these findings coincides with our
growing knowledge for the role of glial cells in every as-
pects of the development and function of neuronal cells,
with the recent evidence that astrocytes play a major
role in neurodevelopmental disorders and the demon-
stration of altered glutamatergic synaptic transmission in
ASD [44, 45]. We propose that abnormal miR-146a ex-
pression impairs astrocyte differentiation and function in
ASD brain and that altered synaptic clearance of glutam-
ate may contribute to the excitatory-inhibitory activity
imbalance underlying autism.
Remarkably, miR-146a overexpression is not restricted
to ASD patients. First, we demonstrated that miR-146a
overexpression is also observed in cells from patients
with ID. Second, increased amount of miR-146a has
been found in epilepsy-associated glioneuronal lesions
[46], in serum of epilepsy patients [47] as well as in the
hippocampus in a rat model of temporal lobe epilepsy
[48]. miR-146a upregulation seems thus to be a common
hallmark of different neurodevelopmental disorders and
may mediate common pathways underlying these condi-
tions. Understanding how this miRNA contributes to the
interactions between synaptic function and immune
molecules and cells will therefore have broad implications.
Lastly, our findings may have important consequences
for the development of future therapies, as several strat-
egies have been established to restore miRNA levels or
block miRNA function. The expression levels of particu-
lar miRNAs can be restored either with miRNA mimics
or with miRNAs encoded in expression vectors. Con-
versely, current strategies for inhibitory targeting of
microRNAs are mainly based on antisense oligonucleo-
tides (so-called anti-miRNAs), comprised of locked nu-
cleic acids (LNA) along with tiny LNA anti-miRNA
constructs, antagomirs, and miRNA sponges [49–51].
Indeed, it was recently shown that intracerebroventricu-
lar injections of antagomir-155 and antagomir-802 in
the Ts65Dn mice, a Down syndrome mouse model that
overexpress such miRNAs, resulted in the attenuation of
30–40 % of endogenous miRNA-155 and miR-802 and
increased Mecp2 target gene expression 7 days after
administration [52]. While manipulating miRNAs expres-
sion to achieve biological levels still requires optimization,
our results support the idea that it might be a promising
strategy in the field of ASD. Further studies are needed to
address the precise molecular mechanisms underlying
miRNA expression deregulation, and whether this is the
consequence of a transcriptional defect or of a miRNA
maturation processing defect need further clarifica-
tion. Investigation in animal models will also be ne-
cessary to determine the exact impact of miR-146a
and miR-221 deregulation on synaptogenesis and
synaptic plasticity.
Conclusions
We identified a signature of four miRNAs commonly
deregulated in ASD and show that this signature is
partially conserved in primary skin fibroblasts. While
the final demonstration of our findings is awaiting the
replication across a larger number of patients, we propose
that this miRNA signature may allow discriminating
between ASD and intellectual disability samples.
The deregulated miRNAs target neuronal relevant
genes and pathways, and we demonstrated altered levels
of corresponding transcripts in patients’ cells. More
importantly, we demonstrated that abnormal expression
of one of these miRNAs (miR-146a) alters neuronal
dendritic complexity and astrocyte glutamate uptake
capacities, providing a convincing link between miRNAs
deregulation and ASD pathophysiology.
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